终末期肾病患者日间嗜睡的管理指南
综述聚焦维持性透析及肾移植成功后患者常见的日间嗜睡(嗜睡症),指出其可继发于躯体共病、药物副作用、睡眠不足综合征、睡眠呼吸障碍或原发性中枢性嗜睡症(如发作性睡病)。未识别和未治疗的睡眠障碍与终末期肾病患者显著发病率和死亡率相关,有效管理可改善生活质量;综述提供识别、早期诊断和治疗的系统化方法,并提出未来研究方向。
要点
- 日间嗜睡在透析及肾移植患者中常见,需警惕继发与原发性病因。
- 未识别和未治疗的睡眠障碍与终末期肾病高发病率和死亡率相关。
- 肾内科医生应主动识别、早期诊断并治疗嗜睡以改善患者生活质量。
核心结论
- 日间嗜睡在终末期肾病患者中常见,有效管理可改善生活质量,肾内科医生应掌握系统化识别、早期诊断与治疗方法。
研究设计与样本
- 综述,聚焦终末期肾病患者日间嗜睡的主要原因,提供识别、早期诊断和治疗的系统化方法,并提出未来研究方向。
主要发现
- 日间嗜睡可继发于躯体共病、药物副作用、睡眠不足综合征、睡眠呼吸障碍,或为原发性中枢性嗜睡症如发作性睡病。
- 未识别和未治疗的睡眠障碍与终末期肾病患者显著发病率和死亡率相关。
临床怎么用
- 肾内科医生应提高对终末期肾病患者嗜睡相关疾病的警觉,按综述提供的系统化方法进行识别、早期诊断和治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daytime sleepiness, also known as hypersomnolence, is common among patients receiving maintenance dialysis and following successful kidney transplantation. Sleepiness may be secondary to medical comorbid conditions, medication side effect, insufficient sleep syndrome, and sleep-disordered breathing or the result of a primary central disorder of hypersomnolence, such as narcolepsy. Unrecognized and untreated sleep disorders are associated with substantial morbidity and mortality among patients with end-stage kidney disease. Effective management of hypersomnolence can improve quality of life in patients with kidney disease. This review focuses on the principal causes of sleepiness in patients with end-stage kidney disease. Awareness of these disorders by treating nephrologists is crucial. This review provides a systematic approach to guide providers through the recognition, early diagnosis, and treatment of hypersomnolence, which is commonly encountered in this patient population. Areas of future research are also suggested.
引用
- So JY, Warburton KM, Rosen IM, et al. A Guide to Management of Sleepiness in ESKD. Am J Kidney Dis. 2020. PMID: 31983503. doi:10.1053/j.ajkd.2019.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。